

CYTODYN INC  
Form 8-K/A  
August 19, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 29, 2015**

**CytoDyn Inc.**

**(Exact name of registrant as specified in charter)**

**Colorado**

**(State or other jurisdiction of incorporation)**

**000-49908**

**(SEC File Number)**

**75-3056237**

**(IRS Employer Identification No.)**

**1111 Main Street, Suite 660**

**Vancouver, Washington**  
**(Address of principal executive offices)**

**98660**  
**(Zip Code)**

**Registrant's telephone number, including area code: (360) 980-8524**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into Material Definitive Agreement.**

This Form 8-K/A (this Amendment ) amends the Current Report on Form 8-K previously filed by CytoDyn Inc. on August 4, 2015 (the Prior Form 8-K and, together with this Amendment, this Form 8-K ). This Amendment is for the sole purpose of filing a copy of the License Agreement (the Agreement ) between CytoDyn and Lonza Sales AG, dated as of July 29, 2015, as an exhibit to this Form 8-K, as previously reported in the Prior Form 8-K. Other than specifically set forth in this Amendment, this Amendment does not change any of the other information contained in the Prior Form 8-K.

A copy of the Agreement is filed as Exhibit 10.1 to this Form 8-K and is incorporated by reference into this Item 1.01.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit

No.	Description
10.1	License Agreement between CytoDyn Inc. and Lonza Sales AG dated July 29, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CytoDyn Inc.**

Dated: August 19, 2015

By: /s/ Michael D. Mulholland  
Michael D. Mulholland

Chief Financial Officer

**EXHIBIT INDEX**

Exhibit

No.	Description
10.1	License Agreement between CytoDyn Inc. and Lonza Sales AG dated July 29, 2015.